Product Details:
- Product Name: Ginsenoside Rg3
- CAS Number: 14197-60-5
- Purity: ≥98% HPLC
- Molecular Formula: C42H72O13
- Molecular Weight: 785.01 g/mol
- Appearance: White to off-white powder
- Solubility: Soluble in water, DMSO, and ethanol
- Storage: Store at -20°C, protected from light and moisture
Features & Benefits:
- Anticancer Activity: Demonstrates significant potential in inhibiting tumor growth and enhancing the efficacy of chemotherapy.
- Anti-inflammatory Effects: Reduces inflammation, offering therapeutic benefits in managing various inflammatory conditions.
- Immune Modulation: Strengthens the immune system, enhancing the body’s defense mechanisms against diseases.
- Cardiovascular Protection: Supports heart health and improves blood circulation, contributing to cardiovascular wellness.
- Fatigue Reduction: Aids in combating fatigue, enhancing physical performance and energy levels.
Applications:
- Pharmaceuticals: Explored for its potential in cancer therapy, immune system support, and cardiovascular health treatments.
- Nutraceuticals: Utilized in dietary supplements for its health-promoting effects, particularly in immune enhancement and energy boosting.
- Functional Foods and Beverages: Incorporated into health-oriented products to leverage its therapeutic benefits.
- Scientific Research: A focus of extensive research to explore its pharmacodynamics, mechanisms of action, and therapeutic potential.
Safety & Compliance:
- Produced under strict quality control standards to ensure high purity and safety.
- Accompanied by a comprehensive Certificate of Analysis (CoA) for quality assurance.
- Recommended for use by professionals and researchers familiar with the handling and safety protocols of bioactive compounds.
Packaging:
- Available in 20mg and 1g quantities to support both research and commercial applications.
- Packaged in air-tight containers to ensure stability and extend shelf life.
Details
CAS# | 14197-60-5 |
---|---|
Purity | ≥98%HPLC |
Package | 20mg;1g |
Reviews
There are no reviews yet.